JTO Clinical and Research Reports最新文献

{"title":"Improving Lung Cancer Screening Selection: The HUNT Lung Cancer Risk Model for Ever-Smokers Versus the NELSON and 2021 United States Preventive Services Task Force Criteria in the Cohort of Norway: A Population-Based Prospective Study","authors":"Olav Toai Duc Nguyen MD ,&nbsp;Ioannis Fotopoulos MS ,&nbsp;Maria Markaki PhD ,&nbsp;Ioannis Tsamardinos PhD ,&nbsp;Vincenzo Lagani PhD ,&nbsp;Oluf Dimitri Røe PhD","doi":"10.1016/j.jtocrr.2024.100660","DOIUrl":"10.1016/j.jtocrr.2024.100660","url":null,"abstract":"<div><h3>Background</h3><p>Improving the method for selecting participants for lung cancer (LC) screening is an urgent need. Here, we compared the performance of the Helseundersøkelsen i Nord-Trøndelag (HUNT) Lung Cancer Model (HUNT LCM) versus the Dutch-Belgian lung cancer screening trial (Nederlands-Leuvens Longkanker Screenings Onderzoek (NELSON)) and 2021 United States Preventive Services Task Force (USPSTF) criteria regarding LC risk prediction and efficiency.</p></div><div><h3>Methods</h3><p>We used linked data from 10 Norwegian prospective population-based cohorts, Cohort of Norway. The study included 44,831 ever-smokers, of which 686 (1.5%) patients developed LC; the median follow-up time was 11.6 years (0.01–20.8 years).</p></div><div><h3>Results</h3><p>Within 6 years, 222 (0.5%) individuals developed LC. The NELSON and 2021 USPSTF criteria predicted 37.4% and 59.5% of the LC cases, respectively. By considering the same number of individuals as the NELSON and 2021 USPSTF criteria selected, the HUNT LCM increased the LC prediction rate by 41.0% and 12.1%, respectively. The HUNT LCM significantly increased sensitivity (<em>p</em> &lt; 0.001 and <em>p</em> = 0.028), and reduced the number needed to predict one LC case (29 versus 40, <em>p</em> &lt; 0.001 and 36 versus 40, <em>p</em> = 0.02), respectively. Applying the HUNT LCM 6-year 0.98% risk score as a cutoff (14.0% of ever-smokers) predicted 70.7% of all LC, increasing LC prediction rate with 89.2% and 18.9% versus the NELSON and 2021 USPSTF, respectively (both <em>p</em> &lt; 0.001).</p></div><div><h3>Conclusions</h3><p>The HUNT LCM was significantly more efficient than the NELSON and 2021 USPSTF criteria, improving the prediction of LC diagnosis, and may be used as a validated clinical tool for screening selection.</p></div>","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":"5 4","pages":"Article 100660"},"PeriodicalIF":0.0,"publicationDate":"2024-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666364324000304/pdfft?md5=00839b6333cd7528fc1221818186bf2d&pid=1-s2.0-S2666364324000304-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140088828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prolonged Cancer Control With Adagrasib in Patients With Metastatic, KRASG12C-Mutated NSCLC After Sotorasib-Induced Hepatotoxicity: A Case Report","authors":"Natalie Stratton BS,&nbsp;Jonathan Thompson MD, MS","doi":"10.1016/j.jtocrr.2024.100661","DOIUrl":"https://doi.org/10.1016/j.jtocrr.2024.100661","url":null,"abstract":"<div><p>Both sotorasib and adagrasib are approved for use in metastatic <em>KRAS</em>^{<em>G12C</em>}-mutated NSCLC after cancer progression on chemotherapy and immunotherapy. Hepatoxicity is a commonly encountered adverse effect of both agents, and little data exists about the safety of sequential use of these agents when hepatotoxicity is encountered. In this case report, we describe a patient who developed recurrent hepatotoxicity with sotorasib and was able to switch to adagrasib without hepatotoxicity and subsequently experienced a prolonged cancer response. We also describe a previously unreported adagrasib adverse effect of photoinduced skin hyperpigmentation.</p></div>","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":"5 4","pages":"Article 100661"},"PeriodicalIF":0.0,"publicationDate":"2024-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666364324000316/pdfft?md5=cc626ad9bfb8247925b9d32c71b74529&pid=1-s2.0-S2666364324000316-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140195514","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Symptomatic Pneumonitis With Durvalumab After Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC","authors":"Johan F. Vansteenkiste MD, PhD ,&nbsp;Jarushka Naidoo MB, BCH, MHS ,&nbsp;Corinne Faivre-Finn MD, PhD ,&nbsp;Mustafa Özgüroğlu MD ,&nbsp;Augusto Villegas MD ,&nbsp;Davey Daniel MD ,&nbsp;Shuji Murakami MD ,&nbsp;Rina Hui M.B.B.S., PhD ,&nbsp;Ki Hyeong Lee MD ,&nbsp;Byoung Chul Cho MD, PhD ,&nbsp;Kaoru Kubota MD, PhD ,&nbsp;Helen Broadhurst MSc ,&nbsp;Catherine Wadsworth BVSc ,&nbsp;Michael Newton PharmD ,&nbsp;Piruntha Thiyagarajah MD ,&nbsp;Scott J. Antonia MD","doi":"10.1016/j.jtocrr.2024.100638","DOIUrl":"10.1016/j.jtocrr.2024.100638","url":null,"abstract":"<div><h3>Introduction</h3><p>In the placebo-controlled, phase 3 PACIFIC trial, durvalumab significantly prolonged progression-free survival (PFS) (<em>p</em> &lt; 0.0001) and overall survival (OS) (<em>p</em> = 0.00251) in patients with unresectable stage III NSCLC and no progression after platinum-based concurrent chemoradiotherapy (cCRT). Pneumonitis or radiation pneumonitis (PRP) was common in both arms. We report exploratory analyses evaluating the association of symptomatic (grade ≥2) PRP (G2+PRP) with baseline factors and clinical outcomes.</p></div><div><h3>Methods</h3><p>Patients with WHO performance status of 0 or 1 were randomized (2:1) to 12 months of durvalumab or placebo, 1 to 42 days after cCRT. Associations between baseline factors and on-study G2+PRP in durvalumab-treated patients were investigated using univariate and multivariate logistic regression. PFS and OS were analyzed using Cox proportional hazards models adjusted for time-dependent G2+PRP plus covariates for randomization stratification factors without and with additional baseline factors.</p></div><div><h3>Results</h3><p>On-study G2+PRP occurred in 94 of 475 (19.8%) and 33 of 234 patients (14.1%) on durvalumab and placebo, respectively (median follow-up, 25.2 mo); grade greater than or equal to 3 PRP was uncommon (4.6% and 4.7%, respectively). Time to onset and resolution of G2+PRP was similar with durvalumab and placebo. Univariate and multivariate analyses identified patients treated in Asia, those with stage IIIA disease, those with performance status of 1, and those who had not received induction chemotherapy as having a higher risk of G2+PRP. PFS and OS benefit favoring durvalumab versus placebo was maintained regardless of time-dependent G2+PRP.</p></div><div><h3>Conclusions</h3><p>Factors associated with higher risk of G2+PRP with durvalumab after cCRT were identified. Clinical benefit was maintained regardless of on-study G2+PRP, suggesting the risk of this event should not deter the use of durvalumab in eligible patients with unresectable stage III NSCLC.</p></div>","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":"5 3","pages":"Article 100638"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666364324000080/pdfft?md5=e11d6edcce61f0ea2764ec8ec5b9621b&pid=1-s2.0-S2666364324000080-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139634640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lung Cancer Screening: An Opportunity to Promote Physical Activity?","authors":"Alice Avancini PhD ,&nbsp;Lorenzo Belluomini MD ,&nbsp;Morten Quist PhD ,&nbsp;Sara Pilotto MD, PhD","doi":"10.1016/j.jtocrr.2024.100651","DOIUrl":"https://doi.org/10.1016/j.jtocrr.2024.100651","url":null,"abstract":"","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":"5 3","pages":"Article 100651"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666364324000213/pdfft?md5=adcdd34f9c88399efd300093b8051998&pid=1-s2.0-S2666364324000213-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140069454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Impact of Immunotherapy Use in Stage IIIA (T1-2N2) NSCLC: A Nationwide Analysis","authors":"Lye-Yeng Wong MD ,&nbsp;Douglas Z. Liou MD ,&nbsp;Mohana Roy MD ,&nbsp;Irmina A. Elliott MD ,&nbsp;Leah M. Backhus MD ,&nbsp;Natalie S. Lui MD ,&nbsp;Joseph B. Shrager MD ,&nbsp;Mark F. Berry MD","doi":"10.1016/j.jtocrr.2024.100654","DOIUrl":"https://doi.org/10.1016/j.jtocrr.2024.100654","url":null,"abstract":"<div><h3>Introduction</h3><p>Multiple clinical trials have revealed the benefit of immunotherapy (IO) for NSCLC, including unresectable stage III disease. Our aim was to investigate the impact of IO use on treatment and outcomes of potentially resectable stage IIIA NSCLC in a broader nationwide patient cohort.</p></div><div><h3>Methods</h3><p>We queried the National Cancer Database (2004–2019) for patients with stage IIIA (T1-2N2) NSCLC. Treatment and survival were evaluated with descriptive statistics, logistic regression, Kaplan-Meier analysis, and Cox proportional hazards modeling.</p></div><div><h3>Results</h3><p>Overall, 5.5% (3777 of 68,335) of patients received IO. IO use was uncommon until 2017, but by 2019, it was given to 40.1% (1544 of 2308) of stage IIIA patients. The increased use of IO after 2017 was associated with increased definitive chemoradiation treatment (54.2% [6800 of 12,535] from years 2017 to 2019 versus 46.9% [26,251 of 55,914] from 2004 to 2016, <em>p</em> &lt; 0.001) and less use of surgery (18.1% [2266 of 12,535] from years 2017 to 2019 versus 22.0% [12,300 of 55,914] from 2004 to 2016, <em>p</em> &lt; 0.001). IO treatment was associated with significantly better 5-year survival in the entire cohort (36.9% versus 23.4%, <em>p</em> &lt; 0.001) and the subsets of patients treated with chemoradiation (37.2% versus 22.7%, <em>p</em> &lt; 0.001) and surgery (48.6% versus 44.3%, <em>p</em> &lt; 0.001). Pneumonectomy use decreased with increased IO treatment (5.1% of surgical patients [116 of 2266] from years 2017 to 2019 versus 9.2% [1127 of 12,300] from 2004 to 2016, <em>p</em> &lt; 0.001).</p></div><div><h3>Conclusions</h3><p>Increased use of IO was associated with a change in treatment patterns and improved survival for patients with stage IIIA(N2) NSCLC.</p></div>","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":"5 3","pages":"Article 100654"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666364324000249/pdfft?md5=f961008e8d25b6e4a581025b662bb3d8&pid=1-s2.0-S2666364324000249-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140069455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Initial Safety and Feasibility Results From a Phase 1, Diagnose-and-Treat Trial of Neoadjuvant Intratumoral Cisplatin for Stage IV NSCLC","authors":"Farrah B. Khan MD ,&nbsp;Pamela C. Gibson MD ,&nbsp;Scott Anderson MD ,&nbsp;Sarah Wagner BS ,&nbsp;Bernard F. Cole PhD ,&nbsp;Peter Kaufman MD ,&nbsp;C. Matthew Kinsey MD, MPH","doi":"10.1016/j.jtocrr.2024.100634","DOIUrl":"https://doi.org/10.1016/j.jtocrr.2024.100634","url":null,"abstract":"<div><p>Neoadjuvant intratumoral cisplatin has the potential to generate substantial cytotoxicity and immune priming within the tumor environment, while minimizing systemic, off-target, adverse events. We initiated a phase 1A, 3+3 dose-ranging study of neoadjuvant, intratumoral cisplatin, delivered through endobronchial ultrasound bronchoscopy, in the same procedure as the initial diagnosis. There were no dose-limiting toxicity identified at the 20mg level</p></div>","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":"5 3","pages":"Article 100634"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666364324000043/pdfft?md5=483f88bb4f86b69307ea20a182f6c519&pid=1-s2.0-S2666364324000043-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140031366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biomarker Testing, Targeted Therapy and Clinical Trial Participation by Race Among Patients With Lung Cancer: A Real-World Medicaid Database Study","authors":"Debora S. Bruno MD, MS ,&nbsp;Xiaohong Li MPH ,&nbsp;Lisa M. Hess PhD","doi":"10.1016/j.jtocrr.2024.100643","DOIUrl":"10.1016/j.jtocrr.2024.100643","url":null,"abstract":"<div><h3>Introduction</h3><p>Biomarker testing in oncology is fundamental for targeted therapy use and clinical trial participation. Factors contributing to previously identified racial disparities in biomarker testing remain unclear. This study investigated biomarker testing, clinical trial participation, and targeted therapy by race among patients with metastatic lung cancer with Medicaid coverage in the United States.</p></div><div><h3>Methods</h3><p>The Merative MarketScan Medicaid claims database was used for this study to identify patients diagnosed with having metastatic lung cancer between 2017 and 2019 with at least 121 days of follow-up. Racial differences in biomarker testing, clinical trial enrollment, and targeted therapy use were analyzed using chi-square/<em>t</em> tests followed by logistic regression for confounding covariates.</p></div><div><h3>Results</h3><p>A total of 3845 patients were eligible. A total of 970 (25.2%) patients included in this study were Black. Biomarker testing was observed among 57.0%, targeted therapy among 4.6%, and 2.6% of the study cohort had evidence of clinical trial participation. No significant disparities between Black and White races were identified. Younger age and metastatic disease at initial diagnosis were the strongest independent factors associated with increased biomarker testing. Biomarker testing was positively associated with targeted therapy use (OR = 1.69, <em>p</em> = 0.005).</p></div><div><h3>Conclusions</h3><p>Patients with metastatic lung cancer with Medicaid coverage were found to have exceedingly low biomarker testing rates; only 57% had evidence of any biomarker testing. Although no consistent differences between Black and White races were identified, this study calls attention to care experienced by socioeconomically disadvantaged patients with metastatic lung cancer in the United States.</p></div>","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":"5 3","pages":"Article 100643"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666364324000134/pdfft?md5=77600ead9f365e8eab58b497409a8a1c&pid=1-s2.0-S2666364324000134-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139826805","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparing Three Different Anti–Programmed Death-Ligand 1 Antibodies in Immunohistochemical Evaluation of Combined Chemoimmunotherapy Response in Patients With NSCLC: A Prospective Study","authors":"Yuki Katayama MD, PhD ,&nbsp;Tadaaki Yamada MD, PhD ,&nbsp;Kenji Morimoto MD, PhD ,&nbsp;Hiroyuki Fujii MD ,&nbsp;Satomi Morita MD, PhD ,&nbsp;Keiko Tanimura MD, PhD ,&nbsp;Takayuki Takeda MD, PhD ,&nbsp;Asuka Okada MD, PhD ,&nbsp;Shinsuke Shiotsu MD, PhD ,&nbsp;Yusuke Chihara MD, PhD ,&nbsp;Osamu Hiranuma MD ,&nbsp;Takahiro Yamada MD, PhD ,&nbsp;Takahiro Ota MD, PhD ,&nbsp;Taishi Harada MD ,&nbsp;Isao Hasegawa MD, PhD ,&nbsp;Masahiro Iwasaku MD, PhD ,&nbsp;Shinsaku Tokuda MD, PhD ,&nbsp;Noriyuki Tanaka MD, PhD ,&nbsp;Aya Miyagawa-Hayashino MD, PhD ,&nbsp;Koichi Takayama MD, PhD","doi":"10.1016/j.jtocrr.2024.100644","DOIUrl":"https://doi.org/10.1016/j.jtocrr.2024.100644","url":null,"abstract":"<div><h3>Introduction</h3><p>Multiple programmed death-ligand 1 (PD-L1) immunohistochemistry assays performed using different antibodies including DAKO 22C3, DAKO 28-8, and Ventana SP142 PD-L1—predictive markers for response to various immune checkpoint inhibitors in NSCLC—have been approved in several countries. The differences in multiple PD-L1 immunohistochemistry assay results in predicting the therapeutic response to combined chemoimmunotherapy in patients with NSCLC remain unclear.</p></div><div><h3>Methods</h3><p>In this multicenter prospective observational study, we monitored 70 patients with advanced NSCLC treated with combined chemoimmunotherapy at 10 institutions in Japan. The expression of PD-L1 in pretreatment tumors was evaluated using the 22C3, 28-8, and SP142 assays in all patients.</p></div><div><h3>Results</h3><p>The PD-L1 level in tumor cells determined using the 22C3 assay was the highest among the three assays performed with different antibodies. According to the 22C3 assay results, the PD-L1 tumor proportion score greater than or equal to 50% group had a significantly longer progression-free survival period than the PD-L1 tumor proportion score less than 50% group. Nevertheless, the other assays did not reveal remarkable differences in the objective response rate or progression-free survival.</p></div><div><h3>Conclusions</h3><p>In our study, PD-L1 expression determined using the 22C3 assay was more correlated with the therapeutic response of patients with NSCLC treated with combined chemoimmunotherapy than that determined using the 28-8 and SP142 assays. Therefore, the 22C3 assay may be useful for clinical decision-making for patients with NSCLC treated with combined chemoimmunotherapy. Trial registration number: UMIN 000043958.</p></div>","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":"5 3","pages":"Article 100644"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666364324000146/pdfft?md5=6b465a7124f91c9ea13f64ca0b06a8ae&pid=1-s2.0-S2666364324000146-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140015276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Benefits and Harms of Lung Cancer Screening in Individuals With Comorbidities","authors":"Minal S. Kale MD, MPH ,&nbsp;Keith Sigel MD, PhD ,&nbsp;Arushi Arora MPH ,&nbsp;Bart S. Ferket MD, PhD ,&nbsp;Juan Wisnivesky MD, DrPh ,&nbsp;Chung Yin Kong PhD","doi":"10.1016/j.jtocrr.2024.100635","DOIUrl":"10.1016/j.jtocrr.2024.100635","url":null,"abstract":"<div><h3>Introduction</h3><p>Individuals with a history of smoking and a high risk of lung cancer often have a high prevalence of smoking-related comorbidities. The presence of these comorbidities might alter the benefit-to-harm ratio of lung cancer screening by influencing the risk of complications, quality of life, and competing risks of death. Nevertheless, individuals with chronic diseases are underrepresented in screening clinical trials. In this study, we use microsimulation modeling to determine the impact of chronic diseases on lung cancer benefits and harms.</p></div><div><h3>Methods</h3><p>We extended a validated lung cancer screening microsimulation model that comprehensively recapitulates an individual’s lung cancer development, progression, detection, follow-up, treatment, and survival. We parameterized the model to reflect the impact of chronic diseases on complications from invasive testing, quality of life, and mortality in individuals in five-year age categories between the ages of 50 and 80 years. Outcomes included life-years (LY) gained per 100,000 in patients with chronic obstructive pulmonary disease, diabetes mellitus, heart disease, and history of stroke compared with screening-eligible individuals without comorbidities.</p></div><div><h3>Results</h3><p>Among individuals between the ages of 50 and 54 years, we found that the presence of a comorbidity altered the LY gained from screening per 100,000 individuals depending on the comorbidity: 4296 LY with no comorbidities; 3462 LY, 3260 LY, 3031 LY, and 3257 LY with chronic obstructive pulmonary disease, heart disease, diabetes mellitus, and stroke, respectively. We observed greater reductions in LY gained in individuals with two comorbidities; we observed similar patterns for individuals between the ages of 55 and 59 years, 60 and 64 years, 65 and 69 years, 70 and 74 years, and 75 and 80 years.</p></div><div><h3>Conclusions</h3><p>Comorbidities reduce LY gained from screening per 100,000 compared with no comorbidities, and our results can be used by clinicians when discussing the benefits and harms of screening in their patients with comorbidities.</p></div>","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":"5 3","pages":"Article 100635"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666364324000055/pdfft?md5=0b627dc63eb51da85b2b89dffb3e06a2&pid=1-s2.0-S2666364324000055-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139539906","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rapid Response to Lenvatinib and Disease Flare After Discontinuation in a Patient With Thymic Carcinoma Harboring KIT Exon 11 Mutation: A Case Report","authors":"Masahiro Torasawa MD ,&nbsp;Tatsuya Yoshida MD, PhD ,&nbsp;Kouya Shiraishi PhD ,&nbsp;Naoko Goto BS ,&nbsp;Toshihide Ueno PhD ,&nbsp;Hitoshi Ichikawa MD, PhD ,&nbsp;Shigehiro Yagishita MD, PhD ,&nbsp;Shinji Kohsaka MD, PhD ,&nbsp;Yasushi Goto MD, PhD ,&nbsp;Yasushi Yatabe MD, PhD ,&nbsp;Akinobu Hamada PhD ,&nbsp;Hiroyuki Mano MD, PhD ,&nbsp;Yuichiro Ohe MD, PhD","doi":"10.1016/j.jtocrr.2024.100657","DOIUrl":"https://doi.org/10.1016/j.jtocrr.2024.100657","url":null,"abstract":"<div><p>Lenvatinib, a multitarget tyrosine kinase inhibitor for c-Kit and other kinases, has exhibited promising efficacy in treating advanced or metastatic thymic carcinoma (TC). Here, we present the case of a patient with metastatic TC harboring a <em>KIT</em> exon 11 deletion and amplification. The patient exhibited a remarkable response to lenvatinib but experienced rapid disease progression after discontinuation of lenvatinib, referred to as a “disease flare.” This case report indicates that <em>KIT</em> mutations and amplification can predict lenvatinib response in patients with TC. However, in such cases, there might be a risk of disease flares after lenvatinib discontinuation.</p></div>","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":"5 4","pages":"Article 100657"},"PeriodicalIF":0.0,"publicationDate":"2024-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666364324000274/pdfft?md5=b9ec22f6643d5497789d13c673ed5b47&pid=1-s2.0-S2666364324000274-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140163115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}